Tag: form

Press Release

Bigbank AS (registry code 10183757, address Riia tn 2, Tartu, 51004) (“Bigbank”) hereby announces a public offering (the “Offering”) of its unsecured subordinated bonds. The Offering is conducted pursuant to the prospectus (the “Prospectus”) prepared by Bigbank and registered by the Estonian Financial Supervision and Resolution Authority (“EFSA”) on 9 June 2025. The Prospectus, which provides further details, has been disclosed on the date of this announcement on the websites of Bigbank and the EFSA. 

ניו יורק, June 10, 2025 (GLOBE NEWSWIRE) --

מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, מזכיר לרוכשים את ניירות הערך של  BigBear.ai Holdings, Inc. (NYSE: BBAI) בין התאריכים 31 במרץ 2022 עד 25 במרץ 2025, שני התאריכים כוללים ("התקופה הייצוגית"), את המועד האחרון החשוב של 10 ביוני 2025 להגשת תביעה ייצוגית בניירות ערך.

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline.

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Digimarc Corporation (NASDAQ: DMRC) between May 3, 2024 and February 26, 2025, both dates inclusive (the “Class Period”), of the important July 8, 2025 lead plaintiff deadline.

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against SoundHound AI, Inc. (NASDAQ:SOUN) on behalf of long-term stockholders following a class action complaint that was filed against SoundHound on March 28, 2025 with a Class Period from May 10, 2024 and March 3, 2025. Our investigation concerns whether the board of directors of SoundHound have breached their fiduciary duties to the company.

McCutcheon Agrees with Apollo that Urgent Change is Needed, including Complete Turnover at the Board Level after Years of Value-Destruction

ROCKVILLE, Md. and SUZHOU, China, June 09, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that 13 studies of its core assets - including the novel drug olverembatinib (HQP1351), the investigational Bcl-2 inhibitor lisaftoclax (APG-2575), and the investigational EED inhibitor APG-5918 – will be featured in an oral presentation, multiple poster presentations and multiple online publications at the 2025 European Hematology Association (EHA) Annual Congress taking place in Milan, Italy, from June 12-15, 2025.